Advances of MicroRNAs in Translational Medicine and Immunotherapy of Renal Tumors

doi:10.11910/2227-6394.2016.04.02.05

Abstract
Figure/Table
References (31)
Related Citation (11)

Download: PDF (286 KB) RICH HTML
Export: BibTeX | EndNote (RIS)

Abstract

microRNA (miRNA) is an important molecular component for cells under normal and pathological status，and plays an important role in oncobiology, including the improvement of tumor growth, invasion, angiogenesis and immunoescape by inhibiting the expression of gene miRNAs. Translational medicine can accelerate the industrialization process of transforming scientific research into engineering application, and its application in medicine may lead to the fast shortening of distance between basic research and clinical practice. According to the study of miRNAs in translational medicine, it is discovered that the pathological subtypes of relative diseases can be identified and patients’ survival time and prognosis can be predicted through the expression profiles of miRNAs in tumors, that the invasive examinations can be reduced to realize the diagnosis of tumors by detecting tumor-associated miRNA biomarkers, and that miRNAs can be used for the clinical treatment of tumors. Renal cell carcinoma (RCC) is a common tumor in urinary system, and application of some specific miRNAs as a biomarker for the complementary diagnosis and treatment as well as evaluation of prognosis has become a hot topic in modern medicine. This study mainly analyzed and summarized the latest development in miRNAs and tumor studies, hoping to provide a theoretical basis for the diagnosis and prognosis of renal cancer.

Key words： MicroRNA Translational medicine Renal cell carcinoma Immunotherapy

Corresponding Authors: HUANG Xin-en, E-mail: apjcphuangxinen@163.com

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Xin-en

Cite this article:

HUANG Xin-en. Advances of MicroRNAs in Translational Medicine and Immunotherapy of Renal Tumors[J]. Journal of International Translational Medicine, 2016, 4(2): 103-108.

URL:

http://www.jitm.hk/EN/10.11910/2227-6394.2016.04.02.05 OR http://www.jitm.hk/EN/Y2016/V4/I2/103

1 Sellitti DF, Doi SQ. MicroRNAs in renal cell carcinoma. Microrna, 2015, 4(1): 26-35. DOI: 10.2174/2211536604666150713105247.
2 Keating P, Cambrosio A, Nelson NC. "Triple negative breast cancer": Translational research and the (re)assembling of diseases in post-genomic medicine. Stud Hist Philos Biol Biomed Sci, 2016, 59:20-34. doi: 10.1016/j.shpsc.2016.05.003.
3 Petrozza V, Carbone A, Bellissimo T, et al. Oncogenic microRNAs characterization in clear cell renal cell carcinoma. Int J Mol Sci, 2015, 16(12): 29219-2225. doi: 10.3390/ijms161226160.
4 Wotschofsky Z, Gummlich L, Liep J, et al. Integrated microRNA and mRNA signature associated with the transition from the locally confined to the metastasized clear cell renal cell carcinoma exemplified by miR-146-5p. PLoS One, 2016, 11(2): e0148746. doi: 10.1371/journal.pone.0148746.
5 Mathew LK, Lee SS, Skull N, et al. Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2 alpha activity. Cancer Discov, 2014, 4(1): 53-60. doi: 10.1158/2159-8290.CD-13-0291.
6 Fedorko M, Pacik D, Wasserbauer R, et al. MicroRNAs in the pathogenesis of renal cell carcinoma and their diagnostic and prognostic utility as cancer biomarkers. Int J Biol Markers, 2016, 31(1): e26-e37. doi: 10.5301/jbm.5000174.
7 Allegra D, Bilan V, GaMing A, et a1. Defective DROSHA processing contributes to downregulatian of MiR-15/-16 in chronic lymphocytieleukemia. Leukemia, 2014, 28(1): 98-107. doi: 10.1038/leu.2013.246.
8 Hur K, Toiyama Y, Schetter AJ, et al. Identification of a metastasis-specific MicroRNA signature in human colorectal cancer. J Natl Cancer Inst, 2015, 107(3). pii: dju492. doi: 10.1093/jnci/dju492.
9 Godlewski J, Bronisz A, Nowicki MO, et al. miemRNA-451: A conditional switch controlling glioma cell proliferation and migration. Cell Cycle, 2010, 9(14): 2742-2748. doi: 10.4161/cc.9.14.12248.
10 Wan G, Zhang X, Langley RR, et al. DNA-damage-induced nuclear export of precursor microRNAs is regulated by the ATM-AKT pathway. Cell Reports, 2013, 3(6): 2100-2112. doi: 10.1016/j.celrep.2013.05.038.
11 Lerner RG, Petritsch C. A microRNA-operated switch of asymmetric-to-symmetric cancer stem cell divisions. Nat Cell Biol, 2014, 16(3): 212-214. doi: 10.1038/ncb2924.
12 Hao J, Zhang Y, Deng M, et al. MicroRNA control of epithelial mesenchymal transition in cancer stem cells. Int J Cancer, 2014, 135(5): 1019-1027. doi: 10.1002/ijc.28761.
13 Song SJ, Poliseno L, Song MS, et al. MicroRNA-antagonism regulates breast cancer sternness and metastasis via TET family-dependent chromatin remodeling. Cell, 2013, 154(2): 311-324. doi: 10.1016/j.cell.2013.06.026.
14 Wu C, Zhuang Y, Jiang S, et al. Interaction between Wnt/β-catenin pathway and microRNAs regulates epithelial-mesenchymal transition in gastric cancer (Review). Int J Oncol, 2016, 48(6): 2236-2246. doi: 10.3892/ijo.2016.3480.
15 Li Q, Song W, Wang W, et al. Suppression of epithelial-mesenchymal transition in hepatocellular carcinoma cells by Krüppel-like Factor 4. Oncotarget, 2016. doi: 10.18632/oncotarget.8831.
16 Shen J, Xia W, Khotskaya YB, et al. EGFR modulates micmRNA maturation in response to hypoxia through phosphorylation of AG02. Nature, 2013, 497(7449): 383-387. doi: 10.1038/nature12080.
17 Liu Q, Wang W, Yang X, et al. MicroRNA-146a inhibits cell migration and invasion by targeting RhoA in breast cancer. Oncol Rep, 2016. doi: 10.3892/or.2016.4788.
18 Slaby O, Redova M, Poprach A, et al. Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer, 2012, 51(7): 707-716. doi: 10.1002/gcc.21957.
19 Kurozumi A, Kato M, Goto Y, et al. Regulation of the collagen cross-linking enzymes LOXL2 and PLOD2 by tumor-suppressive microRNA-26a/b in renal cell carcinoma. Int J Oncol, 2016, 48(5): 1837-1846. doi: 10.3892/ijo.2016.3440.
20 Li Y, Li Y, Chen D, et al. miR‑30a‑5p in the tumorigenesis of renal cell carcinoma: A tumor suppressive microRNA. Mol Med Rep, 2016, 13(5): 4085-4094. doi: 10.3892/mmr.2016.5024.
21 Zhang GM, Luo L, Ding XM, et al. MicroRNA-126 inhibits tumor cell invasion and metastasis by downregulating ROCK1 in renal cell carcinoma. Mol Med Rep, 2016, 13(6): 5029-5036. doi: 10.3892/mmr.2016.5160.
22 Kim EA, Kim SW, Nam J, et al. Inhibition of c-FLIPL expression by miRNA-708 increases the sensitivity of renal cancer cells to anti-cancer drugs. Oncotarget, 2016, [Epub ahead of print]. doi: 10.18632/oncotarget.7149.
23 Jin L, Li Y, Liu J, et al. Tumor suppressor miR-149-5p is associated with cellular migration, proliferation and apoptosis in renal cell carcinoma. Mol Med Rep, 2016, 13(6): 5386-5392. doi: 10.3892/mmr.2016.5205.
24 Li Y, Jin L, Chen D, et al. Tumor suppressive miR-196a is associated with cellular migration, proliferation and apoptosis in renal cell carcinoma. Mol Med Rep, 2016. doi: 10.3892/mmr.2016.5251.
25 Smits KM, Paranjape T, Nallur S, et al. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. Clin Cancer Res, 2011, 17(24): 7723-7731. doi: 10.1158/1078-0432.CCR-11-0990.
26 Wynendaele J, Böhnke A, Leucci E, et al. An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Cancer Res, 2010, 70(23): 9641-9649. doi: 10.1158/0008-5472.CAN-10-0527.
27 Xiao H, Zeng J, Li H, et al. MiR-1 downregulation correlates with poor survival in clear cell renal cell carcinoma where it interferes with cell cycle regulation and metastasis. Oncotarget, 2015, 6(15): 13201-13215. doi: 10.18632/oncotarget.3915.
28 Youssef YM, White NM, Grigull J, et al. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol, 2011, 59(5): 721-730.
29 Nofech-Mozes R, Khella HW, Scorilas A, et al. MicroRNA-194 is a marker for good prognosis in clear cell renal cell carcinoma. Cancer Med, 2016, 5(4): 656-664. doi: 10.1002/cam4.631.
30 Fu Q, Liu Z, Pan D, et al. Tumor miR-125b predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection. Cancer Sci, 2014, 105(11): 1427-1434. doi:10.1016/j.eururo.2011.01.004.
31 Das F, Dey N, Bera A, et al. microRNA-214 Reduces IGF-1 receptor expression and downstream mTORC1 signaling in renal carcinoma cells. J Biol Chem, 2016, [Epub ahead of print]. doi/10.1074/jbc.M115.694331.